I am also little disappointed that B-OM has not appeared to have accelerated; however, it is worth noting in the follow up narrative toward the end of the PR that B-OM is that is is being conducted with up to 20 sites and is estimated to be completed in 2Q17. Without going back to look, I am pretty sure the count of up to 20 sites is new information. So maybe it has in fact accelerated from what it would have been with the initial trial locations and 2Q17 is the faster completion date. I don't know...........
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links